296 related articles for article (PubMed ID: 24969182)
1. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
[TBL] [Abstract][Full Text] [Related]
3. Influence of maintenance steroids on the outcomes in deceased-donor kidney transplant recipients exposed to prolonged pretransplantation dialysis.
Sureshkumar KK; Hussain SM; Thai NL; Marcus RJ
Transplant Proc; 2013; 45(1):99-101. PubMed ID: 23375281
[TBL] [Abstract][Full Text] [Related]
4. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.
Sureshkumar KK; Thai NL; Hussain SM; Ko TY; Marcus RJ
Transplantation; 2012 Apr; 93(8):799-805. PubMed ID: 22290269
[TBL] [Abstract][Full Text] [Related]
5. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
6. Impact of steroid maintenance on the outcomes in first-time deceased donor kidney transplant recipients: Analysis by induction type.
Sureshkumar KK; Hussain SM; Thai NL; Ko TY; Nashar K; Marcus RJ
World J Transplant; 2014 Sep; 4(3):188-95. PubMed ID: 25346892
[TBL] [Abstract][Full Text] [Related]
7. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
8. Does Induction Type Influence Outcomes in Kidney Transplant Recipients at Different Phases of Hepatitis B Infection?
Sureshkumar KK; Chopra B
Exp Clin Transplant; 2019 Aug; 17(4):457-460. PubMed ID: 30066624
[TBL] [Abstract][Full Text] [Related]
9. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
[TBL] [Abstract][Full Text] [Related]
10. Influence of steroid maintenance on the outcomes in deceased donor kidney transplant recipients experiencing delayed graft function.
Tangirala B; Marcus RJ; Hussain SM; Sureshkumar KK
Indian J Nephrol; 2013 Nov; 23(6):403-8. PubMed ID: 24339515
[TBL] [Abstract][Full Text] [Related]
11. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
[TBL] [Abstract][Full Text] [Related]
12. Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation.
Patel HV; Kute VB; Vanikar AV; Shah PR; Gumber MR; Engineer DP; Trivedi HL
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):819-22. PubMed ID: 24969194
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
Hao WJ; Zong HT; Cui YS; Zhang Y
Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
[TBL] [Abstract][Full Text] [Related]
14. A comparison of three induction therapies on patients with delayed graft function after kidney transplantation.
Umber A; Killackey M; Paramesh A; Liu Y; Qin H; Atiq M; Lee B; Alper AB; Simon E; Buell J; Zhang R
J Nephrol; 2017 Apr; 30(2):289-295. PubMed ID: 27062485
[TBL] [Abstract][Full Text] [Related]
15. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis.
Sampaio MS; Chopra B; Sureshkumar KK
Transplantation; 2017 Oct; 101(10):2527-2535. PubMed ID: 28475563
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab induction in deceased donor kidney transplantation.
Huang E; Cho YW; Hayashi R; Bunnapradist S
Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
[TBL] [Abstract][Full Text] [Related]
17. Kidney transplantation in hepatitis C-positive recipients: does type of induction influence outcomes?
Sureshkumar KK; Thai NL; Marcus RJ
Transplant Proc; 2012 Jun; 44(5):1262-4. PubMed ID: 22663997
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
19. Primary pediatric deceased-donor kidney transplant recipients outcomes by immunosuppression induction received in the United States.
Riad S; Jackson S; Chinnakotla S; Verghese P
Pediatr Transplant; 2021 Aug; 25(5):e13928. PubMed ID: 33314638
[TBL] [Abstract][Full Text] [Related]
20. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
